Summary
Purpose: To evaluate the activity and toxicity of SarCNU, an oral chloroethylnitrosourea in patients with recurrent or metastatic colorectal cancer who have progressed after first-line chemotherapy. Patients and Methods: Eighteen patients with recurrent or metastatic colorectal cancer following first-line chemotherapy were treated with SarCNU 860 mg/m2 orally day 1, 5 and 9 every 6 weeks. The patient’s median age was 64 and the ECOG performance status was 0 in six, 1 in eleven and 2 in one patients. All patients were evaluable for toxicity and 16 were evaluable for response. Results: There were no objective responses (0%). One patient had stable disease and 15 had progressive disease at their first follow-up assessment. Median survival was 7.36 months (3.75–7.49 95% C.I). Neutropenia and thrombocytopenia were the most severe toxicities (grade 3-4 in six and nine patients respectively). Pulmonary toxicity was also seen in five patients who had a drop of DLCO grade from baseline and two patients who had a fall in FVC from baseline. Conclusions: SarCNU is inactive in recurrent or metastatic colorectal patients who have progressed after first-line chemotherapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
National Cancer Institute of Canada (2002) Canadian cancer statistics 2003. Toronto, Canada, National Cancer Institute of Canada
Nordic Gastrointestinal Tumour Adjuvant Therapy Group (1992) Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol 10:904–11
Saltz LB, Cox JV, Blanke C et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: irinotecan Study Group. N Engl J Med 343:905–14
Goldberg RM, Sargent DJ, Morton RF et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23–0
Grothey A, Sargent D, Goldberg RM et al (2004) Survival of patients with Advanced Colorectal Cancer improves with the availability of fluorouracil-leucovorin, irinotecan and oxaliplatin in the course of treatment. J Clin Oncol 22:1209–214
Rothenberg ML, Oza AM, Bigelow RH et al (2003) Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim Results of a Phase III trial. J Clin Oncol 21:2059–069
Tournigand C, André T, Achille E et al (2004) FOLFIRI followed by FOLFOX 6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229–37
Noë AJ, Malapetsa A, Panasci LC (1993) Transport of (2-chloroethyl) 3-sarcosinamide-1-nitrosourea human glioma cell line SK-MG-1 is mediated by an epinephrine sensitive carrier system. Mol Pharmcol 44:204–09
Noë AJ, Malapetsa A, Panasci LC (1994) Altered cytotoxicity of (2-chloroethyl)-3-sarcosinamide-1-nitrosourea in human glioma cell lines SK-MG-1 and SK-1 correlates with differential transport kinetics. Cancer Res 54:1491–496
Panasci LC, Marcantonio D, Noë AJ (1996) SarCNU (2-chloroethyl-3-sarcinamide-1-nitrosourea): a novel analogue of chloroethylnitrosourea that is transported by the catecholamine uptake carrier, which mediated increased cytotoxicity. Cancer Chem Pharmacol 37:505–08
Weinstein A, Duner-West M, Nelson D et al (1986) Pulmonary toxicity of carmustine in patients treated for malignant glioma. Cancer Tret Rep 70:943–46
Horton J, Mittleman A, Taylor SG (1975) Phase II trials with procarbazine (nsc-77213), streptozotocin (nsc-85998), 6-thioguanine (nsc-752), and CCNU (nsc-79037) in patients with metastatic cancer of the large bowel. Cancer Chemother Rep 59:333–40
Rubin J, Schott AJ, O’Connell MJ, et al. (1984) A Phase II study of the combination 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) and N-(phosphoacetyl)-1-aspartate (PALA) in patients with advanced large bowel cancer. Am J Clin Oncol 7:523–;25
Marcantonio O, Panasci LC, Hollingshead MG et al (1997) 2-chloroethyl-3-sarcosinamide-1-nitrosourea, a novel chloroethylnitrosourea analogue with enhance antitumour activity against human glioma xenografts. Cancer Res 57:3895–;898
Panasci L, Stinson SF, Melnychuk D, Sandor V, Miller WH Jr, Batist G, Patenaude F, Bangash N, Panarello L, Alaoui-Jamali M, Sausville E (2003) SarCNU, a nitrosourea analog on a day 1, 5, and 9 oral schedule: a phase I and pharmacokinetic study in patients with advanced solid tumors. J Clin Oncol 21:232–;0
Fleming TR (1982) One sample multiple testing procedure for phase II clinical trials. Biometrics 38:143–;51
Author information
Authors and Affiliations
Corresponding author
Additional information
Supported by a grant from the Canadian Cancer Society via the National Cancer Institute of Canada.
Rights and permissions
About this article
Cite this article
Wong, R.P., Baetz, T., Krahn, M.J. et al. SarCNU in recurrent or metastatic colorectal cancer: A phase II study of the National Cancer Institute of Canada Clinical Trials Group. Invest New Drugs 24, 347–351 (2006). https://doi.org/10.1007/s10637-006-5730-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-006-5730-2